Bird & Bird advised Canaccord Genuity and Fox-Davies Capital on an oversubscribed placing by CleanTech Lithium

Bird & Bird are delighted to announce that we have advised our longstanding clients, Canaccord Genuity and Fox-Davies Capital, as joint bookrunners on an oversubscribed placing by AIM-listed CleanTech Lithium Plc. The Placing conditionally raised gross proceeds of £8 million at 22 pence per share.

With a vision to support the clean energy transition, CleanTech Lithium explores and develops lithium projects in Chile that are sustainable and environmentally friendly.

Canaccord Genuity is a global firm that delivers wealth management and capital market solutions to various clients, from private individuals to institutions and corporations.

Fox-Davies Capital specialises in providing independent corporate finance and capital markets advice to public and private companies, with a focus on the mining and natural resources sector.

The Bird & Bird team was led by Corporate team partner Michael Dawes, assisted by Corporate associates Zoe Symes and Amy Donlevey.

Michael commented: “Whilst capital markets are difficult at the moment, good projects can still attract funding. We are very pleased to have supported Fox-Davies and Canaccord on this important placing for CleanTech Lithium, a leader in lithium exploration in Chile. This transaction reflects our extensive expertise and experience in mining and cleantech projects, and our dedication to delivering high-quality advice and service to our clients in a complex and dynamic market.


News & Deals

More News & Deals

Deal

Bird & Bird advises World of Women on its transaction to join the Tezos ecosystem

Jul 23 2024

Read More

Deal

Bird & Bird advised EIFFEL GAZ VERT on an investment in the biogas sector

Jul 23 2024

Read More

News

Bird & Bird grows its Finance practice in Italy with the arrival of two new partners

Jul 19 2024

Read More

Deal

Bird & Bird has advised Dopay on its $13.5 million Series A Extension round

Jul 19 2024

Read More

News

Bird & Bird advises iX Biopharma on rights issue

Jul 15 2024

Read More

Deal

Bird & Bird advises HSS on SciRhom’s EUR 63 million Series A financing round

Jul 11 2024

Read More